Safe use of long-acting β-agonists: What have we learnt?

Expert Opinion on Drug Safety

Volumn 10, Issue 5, 2011, Pages 767-778

  Sears, Malcolm R ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

airway inflammation; confounding; exacerbation; inhaled corticosteroid; long acting agonist; masking; mortality; safety

Indexed keywords

BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; PLACEBO; SALBUTAMOL; SALMETEROL;

ASTHMA; COCHRANE LIBRARY; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG FATALITY; DRUG INDUSTRY; DRUG MEGADOSE; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; META ANALYSIS (TOPIC); MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

ADRENERGIC BETA-AGONISTS; ALBUTEROL; ASTHMA; CLINICAL TRIALS AS TOPIC; ETHANOLAMINES; HUMANS; META-ANALYSIS AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 80051989954     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2011.579900     Document Type: Review

References (66)

1. Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008;31:143-78
2. Prenner BM. Role of long-acting beta2-adrenergic agonists in asthma management based on updated asthma guidelines. Curr Opinion Pulm Med 2008;14:57-63
3. WebMD, 111 Eighth Ave, New York, NY 10011, 30 Dec, 2010
4. Chowdhury BA, Dal Pan G. The FDA and safe use of long-acting beta-agonists in the treatment of asthma. N Engl J Med 2010;362:1169-71 This paper summarizes the views of the FDA based on the hearing with the Joint Advisory Committee in 2008 and provides new recommendations and label changes pertaining to the use of LABA in asthma.
5. Sears MR, Taylor DR. The beta 2-agonist controversy: Observations, explanations, and relationship to asthma epidemiology. Drug Safety 1994;11:259-83
6. Crane J, Pearce N, Flatt A, et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-83. Case-control study. Lancet 1989;1:918-22
7. Grainger J, Woodman K, Pearce N, et al. Prescribed fenoterol and death from asthma in New Zealand, 1981 - 7: A further case-control study. Thorax 1991;46:105-11
8. Sears MR, Taylor DR, Print CG, et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 1990;336:1391-6
9. Taylor DR, Sears MR, Herbison GP, et al. Regular inhaled beta agonist in asthma: Effect on exacerbations and lung function. Thorax 1993;48:134-8
10. Sears MR. Epidemiological trends in asthma. Can Respir J 1996;3:261-8
11. Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: Comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. Br Med J 1993;306:1034-7
12. Mann M, Chowdhury B, Sullivan E, et al. Serious asthma exacerbations in asthmatics treated with high-dose formoterol. Chest 2003;124:70-4
13. Bensch G, Lapidus RJ, Levine BE, et al. A randomized, 12-week, placebo-controlled double-blind study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler. Ann Allergy Asthma Immunol 2001;86:19-27
14. Bensch G, Berger WE, Blokhin BM, et al. One-year efficacy and safety of inhaled formoterol dry powder in children with persistent asthma. Ann Allergy Asthma Immunol 2002;89:180-90
15. Wolfe J, LaForce C, Friedman B, et al. Formoterol 24 mcg bid, and serious asthma exacerbations. Chest 2006;129:27-38
16. Nelson HS, Weiss ST, Bleecker ER, et al. The salmeterol multicenter asthma research trial. A comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006;129:15-26
17. McCoy L, Redelings M, Sorvillo F, Simon P. A multiple cause-of-death analysis of asthma mortality in the United States, 1990 - 2001. J Asthma 2005;42:757-63
18. Moorman JE, Rudd RA, Johnson CA, et al. National surveillance for asthma-United States, 1980-2004. MMWR Surveill Summ 2007;56:1-54
19. Wechsler ME, Kunselman SJ, Chinchilli VM, et al. Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): A genotype-stratified, randomized, placebo-controlled, crossover trial. Lancet 2009;374:1754-64
20. Murphy S, Roberts R. 'Black-box' 101: How the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk. J Allergy Clin Immunol 2006;117:34-9
21. Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Meta-analysis: Effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 2006;144:904-12
22. Hagan P. Four in five asthma deaths may be due to long-acting beta agonists. Br Med J 2006;332:1467
23. Ernst P, McIvor A, Ducharme FM, et al. Safety and effectiveness of long-acting inhaled beta-agonist bronchodilators when taken with inhaled corticosteroids. Ann Intern Med 2006;145:692-4
24. Nelson HS, Dorinsky PM. Safety of long-acting beta-agonists. Ann Intern Med 2006;145:706
25. Jaeschke R, O'Byrne PM, Mezja F, et al. The safety of long-acting beta2-agonists among patients with asthma using inhaled corticosteroids. Systematic review and meta-analysis. Am J Respir Crit Care Med 2008;178:1009-16
26. Jaeschke R, O'Byrne PM, Nair P, et al. The safety of formoterol among patients with asthma using inhaled corticosteroids. Systematic review and meta-analysis. Pol Arch Med Wewn 2008;118:627-35
27. Rodrigo GJ, Moral VP, Marcos LG, Castro-Rodriguez J. Safety of regular use of long-acting beta agonists as monotherapy or added to inhaled corticosteroids in asthma. A systematic review. Pulm Pharmacol Therap 2009;22:9-19
28. Sears MR, Ottosson A, Radner F, Suissa S. Long-acting beta-agonists: A review of formoterol safety data from asthma clinical trials. Eur Respir J 2009;33:21-32
29. Bateman E, Nelson H, Bousquet J, et al. Meta-analysis: Effects of adding salmeterol to inhaled corticosteroids on serious asthma-related events. Ann Intern Med 2008;149:33-42
30. Cates CJ, Cates MJ. Regular treatment with salmeterol for chronic asthma: Serious adverse events (Review). Cochrane Database Syst Rev 2008;(3):CD006363
31. Cates CJ, Cates MJ, Lasserson TJ. Regular treatment with formoterol for chronic asthma: Serious adverse events (Review). Cochrane Database Syst Rev. 2008;((4)CD006923-
32. Cates CJ, Lasserson TJ, Jaeschke R. Regular treatment with salmeterol and inhaled steroids for chronic asthma: Serious adverse events (Review). Cochrane Database Syst Rev. 2009;((3)CD006922- This Cochrane analysis poses the appropriate question regarding the risks when LABA is added to ICS, and found no significant differences in asthma deaths and serious adverse events.
33. Levenson M. Long-acting beta-agonists and adverse asthma events meta-analysis. Statistical briefing package for joint meeting of the Pulmonary-Allergy Drugs Advisory Committee, Drug Safety and Risk Management Advisory Committee and Pediatric Advisory Committee, December 10-11, 2008. Available from: Http://www.fda.gov/ohrms/dockets/ac/ cder08. html#PulmonaryAllergy This on-line report provides detail of the background to, and results of, the independent meta-analysis of LABA safety undertaken by the FDA in preparation for the December 2008 Joint Advisory Committee meeting and includes stratified analyses examining the effects of concomitant ICS therapy.
34. Lemanske RF, Sorkness CA, Mauger EA, et al. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol. A randomized controlled trial. JAMA 2001;285:2594-603
35. McIvor RA, Pizzichini E, Turner MO, et al. Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med 1998;158:924-30
36. Thomas M, von Ziegenweidt J, Lee AJ, Price D. High-dose inhaled corticosteroids versus add-on long-acting beta-agonists in asthma: An observational study. J Allergy Clin Immunol 2009;123:116-21 This real-world study compared effects of adding LABA versus increasing ICS doses to control asthma, and reported fewer hospitalizations and courses of oral corticosteroid with increased ICS indicating better control of inflammation, although there was less use of reliever inhaler in the group with added LABA.
37. Vaessen-Verberne AAPH, van den Berg NJ, van Nierop JC, et al. Combination therapy salmeterol/ fluticasone versus doubling dose of fluticasone in children with asthma. Am J Respir Crit Care Med 2010;182:1221-7
38. Sindi A, Todd DC, Nair P. Antiinflammatory effects of long-acting beta2-agonists in patients with asthma: A systematic review and meta-analysis. Chest 2009;136:145-54
39. Salpeter SR, Wall AJ, Buckley NS. Long-acting beta-agonists with and without inhaled corticosteroids and catastrophic asthma events. Am J Med 2010;123:322-8
40. Kelsen SG, Church NL, Gillman SA, et al. Salmeterol added to inhaled corticosteroid therapy is superior to doubling the dose of inhaled corticosteroids: A randomized clinical trial. J Asthma 1999;36:703-15
41. O'Byrne PM, Barnes PJ, Rodriguez-Roison R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma. The OPTIMA randomized trial. Am J Respir Crit Care Med 2001;164:1392-7
42. Ind PW, Dal Negro R, Colman NC, et al. Addition of salmeterol to fluticasone propionate treatment in moderate-to-severe asthma. Respir Med 2003;97:555-62
43. O'Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005;171:129-36
44. Bisgaard H, Le Roux P, Bjamer D, et al. Budesonide/formoterol maintenance plus reliever therapy: A new strategy in pediatric asthma. Chest 2006;130:1733-43
45. Kramer JM. Balancing the benefits and risks of inhaled long-acting beta-agonists - the influence of values. N Engl J Med 2009;360:1592-5
46. Gamble J, Stevenson M, McClean E, Heaney LG. The prevalence of nonadherence in difficult asthma. Am J Respir Crit Care Med 2009;180:817-22
47. Hasford J, Uricher J, Tauscher M, et al. Persistence with asthma treatment in low in Germany especially for controller medication - a population based study of 483 051 patients. Allergy 2010;65:347-54
48. Williams LK, Peterson EL, Wells K, et al. A cluster-randomized trial to provide clinicians inhaled corticosteroid adherence information for their patients with asthma. J Allergy Clin Immunol 2010;126:225-31
49. Stanford RH, Gilsenan AW, Ziemiecki R, et al. Predictors of uncontrolled asthma in adult and pediatric patients: Analysis of the asthma control characteristics and prevalence survey studies (ACCESS). J Asthma 2010;47:257-62
50. Lemanske RF, Busse WW. The US Food and Drug Administration and long-acting beta2-agonists: The importance of striking the right balance between risks and benefits of therapy? J Allergy Clin Immunol 2010;126:449-52 The authors review the recent FDA recommendations, agreeing in part but expressing major concern regarding the directive to withdraw LABA when control is achieved on combination therapy.
51. Reddel HK, Gibson PG, Peters MJ, et al. Down-titration from high-dose combination therapy in asthma: Removal of long-acting beta2-agonist. Respir Med 2010;104:1110-20 Patients stepped down from ICS/ LABA to ICS alone required higher doses of ICS to maintain stability and had lower lung function compared with those remaining on LABA-CS combination therapy.
52. Hagiwara M, Delea TE, Stanford RH, Stempel DA. Stepping down to fluticasone propionate or a lower dose of fluticasone propionate/salmeterol combination in asthma patients recently initiating combination therapy. Allergy Asthma Proc 2010;31:203-10
53. Beasley R, Martinez FD, Hackshaw A, et al. Safety of long-acting beta-agonists: Urgent need to clear the air remains. Eur Respir J 2009;33:3-5
54. Drazen JM, O'Byrne PM. Risks of long-acting beta-agonists in achieving asthma control. N Engl J Med 2009;360:1671-2
55. Pauwels RA, Lofdahl C-G, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. New Engl J Med 1997;337:1405-11
56. Sears MR. Safety of long-acting beta-agonists. Are new data really required? Chest 2009;136:604-7 This paper summarizes the data provided in the FDA meta-analysis, and uses these data to calculate the very high numbers of subjects which would be required to adequately resolve safety concerns in a new study.
57. Weatherall M, Wijesinghe M, Perrin K, et al. Meta-analysis of the risks of mortality with salmeterol and the effects of concomitant inhaled corticosteroid therapy. Thorax 2010;65:39-43
58. Sears MR, Radner F. Safety of budesonide/formoterol maintenance and reliever therapy in asthma trials. Respir Med 2009;103:1960-68
59. Cazzola M, Matera MG. Emerging inhaled bronchodilators: An update. Eur Respir J 2009;34:757-69
60. Nair P, Hargreave FE. Measuring bronchitis in airway diseases: Clinical implementation and application. Airway hyperresponsiveness in asthma: Its measurement and clinical significance. Chest 2010;138(Suppl):38S-43S
61. Cowan DC, Cowan JO, Palmay R, et al. Effects of steroid therapy on inflammatory cell subtypes in asthma. Thorax 2010;65:384-90
62. Schleich FN, Seidel L, Sele J, et al. Exhaled nitric oxide thresholds associated with a sputum eosinophil count + 3% in a cohort of unselected patients with asthma. Thorax 2010;65:1039-44
63. Taylor DR, Cowan DC. Assessing airway inflammation. Thorax 2010;65:1031-2
64. Nair P, Kjarsgaard M, Armstrong S, et al. Nitric oxide in exhaled breath is poorly correlated to sputum eosinophils in patients with prednisone-dependent asthma. J Allergy Clin Immunol 2010;126:404-6
65. van Veen IH, ten Brinke A, Gauw SA, et al. Consistency of sputum eosinophilia in difficult-to-treat asthma: A 5-year follow-up study. J Allergy Clin Immunol 2009;124:615-17
66. Al-Samri MT, Benedetti A, Prefontaine D, et al. Variability of sputum inflammatory cells in asthmatic patients receiving corticosteroid therapy: A prospective study using multiple samples. J Allergy Clin Immunol 2010;125:1161-3